Evaluation of cytomegalovirus prophylaxis in low and intermediate risk kidney transplant recipients receiving lymphocyte‐depleting induction
- 1 February 2021
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (4) , e13573
Abstract
Cytomegalovirus (CMV) is a significant cause of morbidity in kidney transplant recipients (KTR). Historically at our institution, KTR with low and intermediate CMV risk received 6 months of valganciclovir if they received lymphocyte depleting induction therapy. This study evaluates choice and duration of CMV prophylaxis based on donor (D) and recipient (R) CMV serostatus and the incidence of post‐transplant CMV viremia in low (D‐/R‐) and intermediate (R+) risk KTR receiving lymphocyte‐depleting induction therapy. A protocol utilizing valacyclovir for 3 months for D‐/R‐ and valganciclovir for 3 months for R+ was evaluated. Adult D‐/R‐ and R+ KTR receiving anti‐thymocyte globulin, rabbit or alemtuzumab induction from 8/20/2016 to 9/30/2018 were evaluated through 1 year post‐transplant. Patients were excluded if their CMV serostatus was D+/R‐, received a multi‐organ transplant, or received basiliximab. Seventy‐seven subjects met the inclusion criteria: 25 D‐/R‐ (4 historic group, 21 experimental group) and 52 R+ (31 historic, 21 experimental). No D‐/R‐ patients experienced CMV viremia. Among the R+ historic and experimental groups, there was no significant difference in viremia incidence (35.5% vs 52.4%; P = .573). Of these cases, the peak viral load was similar between the groups (median [IQR], 67 [P = .711), and there was no difference in the incidence of CMV syndrome (16.1% vs 14.3%; P = 1.000) or CMV related hospitalization (12.9% vs 14.3%; P = 1.000). No patient experienced tissue invasive disease. These results suggest limiting valganciclovir exposure may be possible in low and intermediate risk KTR receiving lymphocyte‐depleting induction therapy with no apparent impact on CMV‐related outcomes.Keywords
This publication has 31 references indexed in Scilit:
- New Developments in the Management of Cytomegalovirus Infection After TransplantationDrugs, 2018
- Assessment of Cytomegalovirus-Specific Cell-Mediated Immunity for the Prediction of Cytomegalovirus Disease in High-Risk Solid-Organ Transplant Recipients: A Multicenter Cohort StudyClinical Infectious Diseases, 2012
- The risk of cytomegalovirus recurrence after kidney transplantationTransplant International, 2011
- An Assessment of Donor‐to‐Recipient Transmission Patterns of Human Cytomegalovirus by Analysis of Viral Genomic VariantsThe Journal of Infectious Diseases, 2009
- Improvement in Long-Term Renal Graft Survival due to CMV Prophylaxis with Oral Ganciclovir: Results of a Randomized Clinical TrialAmerican Journal of Transplantation, 2008
- Delayed-Onset Primary Cytomegalovirus Disease and the Risk of Allograft Failure and Mortality after Kidney TransplantationClinical Infectious Diseases, 2008
- Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survivalTransplant International, 2006
- Risk Factors for Cytomegalovirus Viremia and Disease Developing after Prophylaxis in High-Risk Solid-Organ Transplant RecipientsTransplantation, 2004
- Allograft Rejection Predicts the Occurrence of Late‐Onset Cytomegalovirus (CMV) Disease among CMV‐Mismatched Solid Organ Transplant Patients Receiving Prophylaxis with Oral GanciclovirThe Journal of Infectious Diseases, 2001
- Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal TransplantationNew England Journal of Medicine, 1999